Introgen Therapeutics, Inc.'s INGN 241 Works Synergistically With Avastin(R) To Cut Blood Supply To Cancers

BOSTON, Sept. 19 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) reported data from preclinical studies in which mda-7, the active component of INGN 241, in combination with Avastin® (Bevacizumab), produced a complete and synergistic therapeutic effect in models of lung cancer. INGN 241 and Avastin each inhibit the development of blood vessels in tumors, called angiogenesis, through distinct mechanisms, and the combination of the two agents significantly increases antitumor activity compared to the activity of either agent used alone. Researchers at Introgen and The University of Texas M. D. Anderson Cancer Center conducted the study. Dr. Rajagopal Ramesh, Associate Professor, Department of Thoracic and Cardiovascular Medicine at M. D. Anderson Cancer Center was principal investigator of the study and presented the data today at the 4th Annual Angiogenesis and Vascular Targeting conference held in Boston.